Drug Profile
Nipocalimab - Johnson & Johnson
Alternative Names: Anti-FcRn monoclonal antibody - Johnson & Johnson; JNJ 80202135; M 281Latest Information Update: 13 Feb 2024
Price :
$50
*
At a glance
- Originator Momenta Pharmaceuticals
- Developer Janssen Research & Development; Johnson & Johnson
- Class Anti-inflammatories; Antianaemics; Antirheumatics; Monoclonal antibodies; Recombinant proteins
- Mechanism of Action Neonatal Fc receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Autoimmune haemolytic anaemia; Myasthenia gravis
- Phase II/III Chronic inflammatory demyelinating polyradiculoneuropathy
- Phase II Haemolytic disease of newborn; Myositis; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus
- Phase I Unspecified
Most Recent Events
- 09 Feb 2024 Nipocalimab receives Breakthrough Therapy status for Haemolytic disease of newborn in USA
- 10 Nov 2023 Efficacy and adverse events data from a phase-II clinical trials in Rheumatoid arthritis presented at the ACR Convergence 2023 ( ACR-ARP-2023)
- 10 Nov 2023 Efficacy data from a phase-II clinical trials in Rheumatoid arthritis presented at the ACR Convergence 2023 ( ACR-ARP-2023)